Literature DB >> 12594590

Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport.

Martin Westphal1, Henning Stubbe, Andreas Wilhelm Sielenkämper, Reka Borgulya, Hugo Van Aken, Christian Ball, Hans-Georg Bone.   

Abstract

OBJECTIVE: To determine whether a goal-directed terlipressin infusion increases mean arterial pressure without causing a pulmonary vasopressive effect and whether this response impacts on key parameters of oxygen transport in healthy and endotoxemic sheep. DESIGN AND
SETTING: Prospective controlled trial in a university research laboratory. ANIMALS AND
INTERVENTIONS: Six conscious adult ewes instrumented for chronic study received terlipressin as titrated infusion started with 10 microg x kg(-1) x h(-1) and increased by 5 microg x kg(-1) x h(-1) every 15 min, either until mean arterial pressure was increased by 15 mmHg from baseline, or a maximum of 40 microg x kg(-1) x h(-1) was given. Following 24 h of recovery sepsis was induced and maintained in the same ewes by a continuous infusion of endotoxin ( Salmonella typhosa, 10 ng x kg(-1) min(-1)). After 16 h of endotoxemia the sheep were again treated with terlipressin. MEASUREMENTS AND
RESULTS: Systemic oxygen delivery and consumption were calculated before and after the titration period; hemodynamic parameters were measured every 15 min. The increase in mean arterial pressure was greater during endotoxemia than in healthy controls. In both states terlipressin administration decreased cardiac index and diminished oxygen delivery and consumption. While mean pulmonary arterial pressure remained constant, terlipressin increased the pulmonary vascular resistance index in endotoxemic sheep.
CONCLUSIONS: During ovine endotoxemia titrated terlipressin reversed hypotension but impaired the pulmonary circulation. The observed decrease in oxygen delivery may carry the risk of tissue hypoxia especially in sepsis, where oxygen demand is typically increased.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12594590     DOI: 10.1007/s00134-002-1546-5

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  21 in total

1.  Terlipressin in patients with septic shock: friend or foe?

Authors:  M Westphal; C Ertmer; H Van Aken; H-G Bone
Journal:  Intensive Care Med       Date:  2004-03-27       Impact factor: 17.440

2.  Ventilator associated pneumonia following liver transplantation: Etiology, risk factors and outcome.

Authors:  Antonio Siniscalchi; Lucia Aurini; Beatrice Benini; Lorenzo Gamberini; Stefano Nava; Pierluigi Viale; Stefano Faenza
Journal:  World J Transplant       Date:  2016-06-24

3.  Safety and Efficacy of Terlipressin in Pediatric Distributive Shock: A Retrospective Analysis in 20 Children.

Authors:  Jörg Michel; Michael Hofbeck; Gina Spiller; Hanna Renk; Matthias Kumpf; Felix Neunhoeffer
Journal:  Paediatr Drugs       Date:  2017-02       Impact factor: 3.022

4.  Protective effect of suberoylanilide hydroxamic acid against lipopolysaccharide-induced liver damage in rodents.

Authors:  Yili Zhao; Peter Zhou; Baoling Liu; Ted Bambakidis; Ralph Mazitschek; Hasan B Alam; Yongqing Li
Journal:  J Surg Res       Date:  2014-11-06       Impact factor: 2.192

Review 5.  [Vasopressin and terlipressin in sepsis and systemic inflammatory response syndrome. Effects on microcirculation, oxygen transport, metabolism and organ function].

Authors:  C Ertmer; A W Sielenkämper; H van Aken; H-G Bone; M Westphal
Journal:  Anaesthesist       Date:  2005-04       Impact factor: 1.041

6.  Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study.

Authors:  Andrea Morelli; Christian Ertmer; Sebastian Rehberg; Matthias Lange; Alessandra Orecchioni; Valeria Cecchini; Alessandra Bachetoni; Mariadomenica D'Alessandro; Hugo Van Aken; Paolo Pietropaoli; Martin Westphal
Journal:  Crit Care       Date:  2009-08-10       Impact factor: 9.097

Review 7.  Role of vasopressin in the management of septic shock.

Authors:  Gökhan M Mutlu; Phillip Factor
Journal:  Intensive Care Med       Date:  2004-04-21       Impact factor: 17.440

8.  Current place of vasopressin analogues in the treatment of septic shock.

Authors:  Christian Ertmer; Sebastian Rehberg; Andrea Morelli; Martin Westphal
Journal:  Curr Infect Dis Rep       Date:  2008-09       Impact factor: 3.725

9.  [Vasopressin as a rescue vasopressor agent. Treatment of selected cardiogenic shock states].

Authors:  V D Mayr; G Luckner; S Jochberger; V Wenzel; W R Hasibeder; M W Dünser
Journal:  Anaesthesist       Date:  2007-10       Impact factor: 1.041

Review 10.  Vasopressin vs. terlipressin in the treatment of cardiovascular failure in sepsis.

Authors:  Matthias Lange; Christian Ertmer; Martin Westphal
Journal:  Intensive Care Med       Date:  2007-12-08       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.